Aspergillosis Treatment Market Trends 2020: Latest Devices, Key Players Statistics Data, Regional Business Outlook 2026

Global Aspergillosis Treatment Market

Aspergillosis is a group of diseases that originate from the aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to Aspergillus induced infection. Common Aspergillus infections include invasive Aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma (CPA). Invasive aspergillosis is uncommon and occurs primarily in immunocompromised people. Chronic pulmonary aspergillosis is rare pulmonary disease, which increases symptoms of respiratory disorders such as asthma.

For more information, Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1587

According to a study published by the European Respiratory Society (ERS) publications in 2015, CPA is estimated to affect nearly 240,000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which if left untreated can develop chronic fibrosing pulmonary aspergillosis. According to the statistics provided by the Centers for Disease Control and prevention (CDC), an estimated 10% of individuals with asthma or cystic fibrosis experience an allergic reaction to aspergillus. ABPA is estimated to affect around 2% to 15% of patients with cystic fibrosis and around 2% of all asthma patients.

Global Aspergillosis Treatment Market Dynamics

Increasing prevalence of Aspergillosis and favorable government regulations are the major factors driving growth of the Aspergillosis treatment market. According to a study published in the Journal of Fungi in 2016, CPA is estimated to affect nearly three million people globally making it major health problem resulting in mortality and morbidity. Aspergillosis infection can be treated with antifungal and corticosteroids drugs. Corticosteroid drugs are prescribed for allergic bronchopulmonary aspergillosis treatment. These drugs reduce inflammation and lowers respiratory symptoms such as coughing and wheezing. Some of the most frequently used drugs are methylprednisolone, prednisolone and prednisone. The U.S. Food & Drug Administration (FDA) approved various drugs for Aspergillosis infection treatment.

To get a detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1587

For instance, in 2015, the U.S. FDA approved Isavuconazonium (Astellas Pharma), a prodrug form of Isavuconazole. Antifungal drugs are majorly used to treat invasive pulmonary Aspergillosis. Voriconazole, an antifungal drug is widely used due to less side effects and more effectiveness in comparison to other drugs. Itraconazole or Amphotericin B also treat the infection effectively. Caspofungin is used to treat infection, resistant to the other antifungals. Furthermore, antifungal drugs are sometimes used in combination with corticosteroids for treating ABPA. Surgeries may be required in some cases where aspergillomas are present leading to serious problems such as excessive bleeding. Antifungal drugs are generally not effective against aspergillomas, therefore, surgeries, such as embolization, is recommended. An aspergilloma is a solid mass of Aspergillus hyphae, mucus, fibrin, and other cellular debris, formed inside a pre-existing area of pulmonary cavity or scar. Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market. Moreover, antifungals can also cause serious side effects such as liver and kidney damage.

Global Aspergillosis Treatment Market – Regional Insights

The North America aspergillosis treatment market is expected to hold a dominant position in the global market, due to the increasing governmental initiatives for the diagnosis and treatment of the aspergillus infection. In 2016, the Infectious Diseases Society of America (IDSA) published new guidelines for the diagnosis and treatment of infections due to Aspergillus species. The document offers guidance on non-culture-based identification of Aspergillus infections and dejects the use of combination anti-fungal therapy for primary management. The guidelines also define therapy of isavuconazole, a new U.S. FDA approved anti-fungal drug, in March 2015 to treat mucormycosis and aspergillosis.

Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/1587

The Asia pacific market share is poised to witness substantial growth over the forecast period, owing to a large number of untreated patients. Many countries in the region lack resources for suitable infection diagnostics and control. Opportunistic invasive fungal infections (IFIs) have a substantial impact on public health in the region, which requires early diagnosis and suitable treatment. The occurrence of IFI in the Asia Pacific region is increasing due to increased population of immunosuppressed patients resulting from transplantation and treatments for cancer, as well as the impact of HIV.

Global Aspergillosis Treatment Market – Competitive Analysis

The renowned players operating in the global aspergillosis treatment market include Abbott laboratories, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Services, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., and Takeda Pharmaceutical Company Ltd.

Global Aspergillosis Treatment Market Taxonomy

Based on drugs class:

• Corticosteroids
• Anti-fungal

On the basis of disease type:

• Invasive Aspergillosis
• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis
• Allergic Aspergillus Sinusitis
• Aspergilloma
• Cutaneous Aspergillosis

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.